Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 2/20 | 0.50 |
| ▸ | TACR1 | P25103 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4419690 | 0.86 | KDM4E (0.53) | TACR2TACR1HPGD | |
| SCHEMBL4422024 | 0.85 | HPGD (0.58) | HPGDKMT2A | |
| SCHEMBL4424602 | 0.83 | TACR2 (0.52) | TACR2TACR1 | |
| SCHEMBL4415286 | 0.83 | ALDH1A1 (0.65) | HPGDKMT2A | |
| SCHEMBL4419074 | 0.81 | KDM4E (0.57) | TACR2TACR1HPGD | |
| SCHEMBL4425017 | 0.80 | SLC6A7 (0.56) | HPGD | |
| SCHEMBL4552360 | 0.80 | HSD11B1 (0.67) | TACR2TACR1 | |
| SCHEMBL4422939 | 0.80 | TACR2 (0.47) | TACR2TACR1HPGD | |
| SCHEMBL4419650 | 0.79 | ALDH1A1 (0.53) | TACR2TACR1 | |
| SCHEMBL4429394 | 0.78 | ALDH1A1 (0.55) | TACR2TACR1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | TACR2 1032/4885TACR1 1060/4885HPGD 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.